

*South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2021 - September 30, 2022*

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Internal Medicine					
	63842	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency (HEART-FID)	Dr Malozzi, C	Luitpold Pharmaceuticals, Inc.	10,226.00
	63891	Corrona Inflammatory Bowel Disease (IBD) Registry 600 Registry	(IBD- Dr Sonnier, W	Corrona, LLC	5,600.00
				Total Internal Medicine	15,826.00

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2021 - September 30, 2022

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Neurology	63867	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy (Xenon XPF-008-201)	Dr Naritoku, D	Xenon Pharmaceuticals, Inc.	18,655.85
	63885	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (EMD Serono Ms200527_0080)	Dr Kilgo, W	EMD Serono, Inc.	3,000.00
	63886	A Multicenter, Longitudinal, Open-label, Single-arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (Celgene RPC-1063-MS-001)	Dr Kilgo, W	Celgene International II Sarl	3,367.00
	63894	Advanced Parkinson's Disease: An Open-Label Extension Study of M15-736 Evaluating the Safety and Tolerability of ABBV-951 (AbbVie M20-098)	Dr Dees, D	AbbVie, Inc.	3,000.00
	63909	An Observational Study of Ocrelizumab-Treated Patients With Multiple Sclerosis To Determine The Incidence and Mortality Rates Cancer and All Malignancies (Roche-BA39731-Verismo)	Dr Kilgo, W	Roche	10,025.84
				Total Neurology	38,048.69

*South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2021 - September 30, 2022*

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
OB-GYN					
	63887	A Phase 3, Randomized, Double- or Observer-Blinded, Placebo-Controlled Trial to Evaluate The Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Perfusion FSubunit Vaccine in Infants Born to Women Vaccinated During Pregnancy Investigational (Pfizer C3671008)	Dr Roth, T	Pfizer	175,858.80
				Total OB-GYN	175,858.80
Orthopaedics					
	63908	ProChondrix CR Articular Cartilage Restoration Evaluation (PACE) Registry (PACE Registry)	Dr Slauterbeck, J	AlloSource	8,550.00
				Total OB-GYN	8,550.00
Pediatrics					
	63911	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises (GBT2104-131)	Dr Marri, P	Global Blood Therapeutics, Inc.	11,700.00
	63912	A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants with Sickle Cell Disease and Recurrent Vaso-occlusive Crises (GBT2104-132)	Dr Marri, P	Global Blood Therapeutics, Inc.	11,700.00
	63913	An Open-Label Extension Study to Evaluate the Long-Term Safety of Inclacumab Administered to Participants with Sickle Cell Disease Who Have Participated in an Inclacumab Clinical Trial (GBT2104-133)	Dr Marri, P	Global Blood Therapeutics, Inc.	11,700.00

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2021 - September 30, 2022

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
	63915	Reference Range and Clinical Performance Evaluation of Elecsys IL-6 Assay in Neonatal Sepsis (US); Collection Study (Roche Study #0165/0661)	Dr Eyal, F	Roche Diagnostics Operations, Inc.	9,289.50
	63917	A Phase 1, Randomized, Parallel-group, Open-label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan (10 or 20 mg Once Daily) in Adolescents with Symptomatic Gastroesophageal Reflux Disease (Phathom VPED-102)	Dr Gremse, D	Phathom Pharmaceuticals, Inc.	10,350.00
				Total Pediatrics	54,739.50

South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2021 - September 30, 2022

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Surgery	63857	TAK-954-2004: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-bowel Resection (Millennium TAK-954-2004)	Dr Rider, P	Millennium Pharmaceuticals / Takeda	26,373.02
	63879	Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (MediWound MW2018-06-21)	Dr Bright, A	MediWound	123,526.25
	63910	The CALIBER Study: Randomized Controlled Trial of LINX versus Double-Dose Pump Inhibitor Therapy for Reflux Disease (Torax Rethink Reflux Registry)	Dr Richards, W	Torax Medical, Inc.	18,446.00
	63914	A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection (PROFILE) (Palisade Bio LBS-POI-201)	Dr Rider, P	Palisade	13,277.00
					Total Surgery
Mitchell Cancer Institute	63752	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL) - (CL-PTL-119) (Gradalis CL-PTL-119)	Dr Rocconi, R	Gradalis, Inc.	3,615.00
	63761	Clinical Study Protocol M13-694 A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (Abbvie M13-694)	Dr Scalici, J	GOG / Abbvie	13,640.38
					Total Mitchell Cancer Institute

*South Alabama Medical Science Foundation
Cash Receipts (For Projects Over \$2,000)
October 1, 2021 - September 30, 2022*

Department	Project Number	Project Title	Principal Investigator	Source of Funding	20-21 Receipts
Microbiology					
	63900	The preparatin of 2 SARS-CoV-2 vaccines using nanoemulsion adjuvant and testing the efficacy of those vaccines against challenge with up to two SARS-CoV-2 strains in a hamster model. (Blue Willow Hamster Study)	Dr Rayner, J	Blue Willow Biologics	52,012.40
				Total Microbiology	52,012.40
				Total All Departments	543,913.04
Other Research Related Revenue					
	62648	Royalty On Sales of Antibody Products	Dr Scammell, J	QED Bioscience	2,587.00
				Total Other Research	2,587.00
				Total	546,500.04